Skip To Content
Seock-Ah Im
Department

1   Hemato Oncology

2   Medical Oncology Center

3   Personalized Cancer Medicine Center

Specialty

1   Breast cancer , Gastrointestinal stromal tumor (GIST) , Clinical trial , Personalized treatment

2   Breast cancer , Gastrointestinal stromal tumor (GIST) , Clinical trial , Personalized treatment

3   Breast cancer , Gastrointestinal stromal tumor (GIST) , Clinical trial , Personalized treatment

Appointment

Education / Career

Education / Career
Article Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Announcements LANCET Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33278935/
Education / Career
Article Clinical implications of her2 mrna expression and intrinsic subtype in refractory her2-positive metastatic breast cancer treated with pan-her inhibitor, poziotinib.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32860168/
Education / Career
Article Combined the smac mimetic and bcl2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-trna synthase-positive breast cancer.
Announcements BREAST CANCER RESEARCH Date of publication 2020-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33239070/
Education / Career
Article Hla-b27 association of autoimmune encephalitis induced by pd-l1 inhibitor.
Announcements ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY Date of publication 2020-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33031633/
Education / Career
Article Patient-reported outcomes of palbociclib plus exemestane with gnrh agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (kcsg-br 15-10).
Announcements CANCERS Date of publication 2020-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33167305/
Education / Career
Article Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, her2-positive advanced breast cancer (kate2): a phase 2, multicentre, randomised, double-blind trial.
Announcements LANCET ONCOLOGY Date of publication 2020-0
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33002436/
Education / Career
Article Circulating osteocalcin-positive cells as a novel diagnostic biomarker for bone metastasis in breast cancer patients.
Announcements JOURNAL OF BONE AND MINERAL RESEARCH Date of publication 2020-0
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32379371/
Education / Career
Article Adjuvant chemotherapy in microsatellite instability-high gastric cancer.
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2020-0
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32599979/
Education / Career
Article Olaparib and durvalumab in patients with germline brca-mutated metastatic breast cancer (mediola): an open-label, multicentre, phase 1/2, basket study.
Announcements LANCET ONCOLOGY Date of publication 2020-9
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32771088/
Education / Career
Article Clinicopathological features of patients with the brca1 c.5339t>c (p.leu1780pro) variant.
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2020-7
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32019279/
Education / Career
Article Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors.
Announcements CLINICAL INFECTIOUS DISEASES Date of publication 2020-7
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31680143/
Education / Career
Article Homologous repair deficiency score for identifying breast cancers with defective dna damage response.
Announcements SCIENTIFIC REPORTS Date of publication 2020-7
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32719318/
Education / Career
Article Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on mri findings: a prospective feasibility trial.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2020-7
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32418044/
Education / Career
Article Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, her2-positive advanced breast cancer (monarcher): a randomised, open-label, phase 2 trial.
Announcements LANCET ONCOLOGY Date of publication 2020-6
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32353342/
Education / Career
Article Effect of timing of gonadotropin-releasing hormone agonist administration for ovarian protection in patients with breast cancer.
Announcements JOURNAL OF BREAST CANCER Date of publication 2020-6
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32595989/
Education / Career
Article Antitumor effect of a wee1 inhibitor and potentiation of olaparib sensitivity by dna damage response modulation in triple-negative breast cancer.
Announcements SCIENTIFIC REPORTS Date of publication 2020-6
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32555285/
Education / Career
Article Olaparib monotherapy for asian patients with a germline brca mutation and her2-negative metastatic breast cancer: olympiad randomized trial subgroup analysis.
Announcements SCIENTIFIC REPORTS Date of publication 2020-5
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32472001/
Education / Career
Article Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort keynote-173 study.
Announcements ANNALS OF ONCOLOGY Date of publication 2020-5
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32278621/
Education / Career
Article Prognostic role of androgen receptor expression in surgically resected early breast cancer patients.
Announcements JOURNAL OF BREAST CANCER Date of publication 2020-4
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32395377/
Education / Career
Article Pan-asian adapted esmo clinical practice guidelines for the management of patients with early breast cancer: a ksmo-esmo initiative endorsed by csco, ismpo, jsmo, mos, sso and tos.
Announcements ANNALS OF ONCOLOGY Date of publication 2020-4
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32081575/
Education / Career
Article Development of a nomogram to predict the recurrence score of 21-gene prediction assay in hormone receptor positive early breast cancer.
Announcements CLINICAL BREAST CANCER Date of publication 2020-4
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31522959/
Education / Career
Article Pertuzumab, trastuzumab, and docetaxel for her2-positive metastatic breast cancer (cleopatra): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Announcements LANCET ONCOLOGY Date of publication 2020-4
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32171426/
Education / Career
Article The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: a prospective observational study.
Announcements JOURNAL OF PSYCHOSOMATIC RESEARCH Date of publication 2020-3
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31923732/
Education / Career
Article Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Announcements BREAST CANCER RESEARCH Date of publication 2020-3
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32164785/
Education / Career
Article Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer.
Announcements SUPPORTIVE CARE IN CANCER Date of publication 2020-3
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31264189/
Education / Career
Article Trastuzumab deruxtecan in previously treated her2-positive breast cancer.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31825192/
Education / Career
Article Tdp1 and top1 modulation in olaparib-resistant cancer determines the efficacy of subsequent chemotherapy.
Announcements CANCERS Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32028591/
Education / Career
Article Survival outcomes of breast cancer patients with brain metastases: a multicenter retrospective study in korea (krog 16-12).
Announcements BREAST Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31677532/
Education / Career
Article Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase iii trial.
Announcements JOURNAL OF CLINICAL ONCOLOGY Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31518174/
Education / Career
Article Parp inhibitors as therapeutics: beyond modulation of parylation.
Announcements CANCERS Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32046300/
Education / Career
Article Overall survival with ribociclib plus fulvestrant in advanced breast cancer.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31826360/
Education / Career
Article Bevacizumab as adjuvant treatment of colon cancer: updated results from the s-avant phase iii study by the gercor group.
Announcements ANNALS OF ONCOLOGY Date of publication 2020-2
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31959341/
Education / Career
Article Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naive metastatic breast cancer.
Announcements CLINICAL CANCER RESEARCH Date of publication 2020-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31527167/
Education / Career
Article Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, her2-negative metastatic breast cancer (kcsg-br15-10): a multicentre, open-label, randomised, phase 2 trial.
Announcements LANCET ONCOLOGY Date of publication 2019-2
Co-researcher
Education / Career
Article Randomised phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with her2+metastatic breast cancer after lapatinib and trastuzumab treatment (kcsg br11-16).
Announcements BRITISH JOURNAL OF CANCER Date of publication 2019-2
Co-researcher
Education / Career
Article Targeted next-generation dna sequencing identifies notch signaling pathway mutation as a predictor of radiation response.
Announcements INTERNATIONAL JOURNAL OF RADIATION BIOLOGY Date of publication 2019-2
Co-researcher
Education / Career
Article Contrasting epidemiology and clinicopathology of female breast cancer in asians vs the us population.
Announcements JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE Date of publication 2019-2
Co-researcher
Education / Career
Article Prognostic impact of pregnancy in korean patients with breast cancer.
Announcements ONCOLOGIST Date of publication 2019-2
Co-researcher
Education / Career
Article Amenorrhea and menopause in patients with breast cancer after chemotherapy.
Announcements JOURNAL OF BREAST CANCER Date of publication 2019-1
Co-researcher
Education / Career
Article Exploratory biomarker analysis from a phase ii clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for her2-negative metastatic breast cancer patients (kcsg br13-11).
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2019-1
Co-researcher
Education / Career
Article Treating hr+/her2-breast cancer in premenopausal asian women: asian breast cancer cooperative group 2019 consensus and position on ovarian suppression.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2019-0
Co-researcher
Education / Career
Article Patient-reported outcomes in patients with a germline brca mutation and her2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the olympiad trial.
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2019-0
Co-researcher
Education / Career
Article The her2 s310f mutant can form an active heterodimer with the egfr, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab.
Announcements BIOMOLECULES Date of publication 2019-0
Co-researcher
Education / Career
Article Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in chinese patients with her2-positive early breast cancer.
Announcements ANTI-CANCER DRUGS Date of publication 2019-9
Co-researcher
Education / Career
Article Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2019-7
Co-researcher
Education / Career
Article Overall survival with ribociclib plus endocrine therapy in breast cancer.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2019-7
Co-researcher
Education / Career
Article Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage i-iii breast cancer patients.
Announcements BRITISH JOURNAL OF CANCER Date of publication 2019-7
Co-researcher
Education / Career
Article Quality of life outcomes including neuropathy-associated scale from a phase ii, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for her2-negative metastatic breast cancer: korean cancer study group trial (kcsg br13-11).
Announcements CANCER COMMUNICATIONS Date of publication 2019-5
Co-researcher
Education / Career
Article Molecular alterations and poziotinib efficacy, a pan-her inhibitor, in human epidermal growth factor receptor 2 (her2)-positive breast cancers: combined exploratory biomarker analysis from a phase ii clinical trial of poziotinib for refractory her2-positive breast cancer patients.
Announcements INTERNATIONAL JOURNAL OF CANCER Date of publication 2019-5
Co-researcher
Education / Career
Article Prognostic effects of abnormal dna damage response protein expression in breast cancer.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2019-5
Co-researcher
Education / Career
Article Pan-pim kinase inhibitor azd1208 suppresses tumor growth and synergistically interacts with akt inhibition in gastric cancer cells.
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2019-4
Co-researcher
Education / Career
Article Olympiad final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline brca mutation and her2-negative metastatic breast cancer.
Announcements ANNALS OF ONCOLOGY Date of publication 2019-4
Co-researcher
Education / Career
Article Randomized open label phase iii trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: proceed trial (kcsg br 11-01).
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2019-1
Co-researcher
Education / Career
Article Landscape of actionable genetic alterations profiled from 1,071 tumor samples in korean cancer patients.
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2019-1
Co-researcher
Education / Career
Article Monarch 3 final pfs: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Announcements NPJ BREAST CANCER Date of publication 2019-1
Co-researcher
Education / Career
Article Ribociclib and endocrine therapy in breast cancer reply.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2019-1
Co-researcher
Education / Career
Article A phase ii trial of the pan-her inhibitor poziotinib, in patients with her2-positive metastatic breast cancer who had received at least two prior her2-directed regimens: results of the nov120101-203 trial.
Announcements INTERNATIONAL JOURNAL OF CANCER Date of publication 2018-2
Co-researcher
Education / Career
Article Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Announcements BREAST CANCER RESEARCH AND TREATMENT Date of publication 2018-2
Co-researcher
Education / Career
Article Androgen receptor inhibitor enhances the anti-tumor effect of parp inhibitor in breast cancer cells by modulating dna damage response.
Announcements MOLECULAR CANCER THERAPEUTICS Date of publication 2018-2
Co-researcher
Education / Career
Article Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from azd9496 oral serd phase i trial.
Announcements CLINICAL CANCER RESEARCH Date of publication 2018-2
Co-researcher
Education / Career
Article Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2018-1
Co-researcher
Education / Career
Article Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: overall survival results from belle-2.
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2018-1
Co-researcher
Education / Career
Article Overall survival with palbociclib and fulvestrant in advanced breast cancer.
Announcements NEW ENGLAND JOURNAL OF MEDICINE Date of publication 2018-1
Co-researcher
Education / Career
Article Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in paloma-3.
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2018-1
Co-researcher
Education / Career
Article Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, her2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (kcsg br10-04): a multicentre, open-label, three-arm, randomised phase ii trial (flag study).
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2018-1
Co-researcher
Education / Career
Article Oncologic safety of gonadotropin-releasing hormone agonist for ovarian function protection during breast cancer chemotherapy.
Announcements CLINICAL BREAST CANCER Date of publication 2018-0
Co-researcher
Education / Career
Article Palbociclib plus endocrine therapy in older women with hr+/her2-advanced breast cancer: a pooled analysis of randomised paloma clinical studies.
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2018-9
Co-researcher
Education / Career
Article A first-in-human study of the new oral selective estrogen receptor degrader azd9496 for er+/her2(-) advanced breast cancer.
Announcements CLINICAL CANCER RESEARCH Date of publication 2018-8
Co-researcher
Education / Career
Article Phase iii randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: monaleesa-3.
Announcements JOURNAL OF CLINICAL ONCOLOGY Date of publication 2018-8
Co-researcher
Education / Career
Article Cyclin e overexpression confers resistance to the cdk4/6 specific inhibitor palbociclib in gastric cancer cells.
Announcements CANCER LETTERS Date of publication 2018-8
Co-researcher
Education / Career
Article Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors.
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2018-7
Co-researcher
Education / Career
Article Change in topoisomerase 1-positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.
Announcements CLINICAL CANCER RESEARCH Date of publication 2018-7
Co-researcher
Education / Career
Article Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (monaleesa-7): a randomised phase 3 trial.
Announcements LANCET ONCOLOGY Date of publication 2018-7
Co-researcher
Education / Career
Article Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Announcements CLINICAL CANCER RESEARCH Date of publication 2018-6
Co-researcher
Education / Career
Article Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
Announcements JOURNAL OF PSYCHOSOMATIC RESEARCH Date of publication 2018-5
Co-researcher
Education / Career
Article Subgroup analysis of patients with her2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Announcements BREAST CANCER Date of publication 2018-5
Co-researcher
Education / Career
Article Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors.
Announcements NATURE BIOMEDICAL ENGINEERING Date of publication 2018-4
Co-researcher
Education / Career
Article Phase iii, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of sb3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer.
Announcements JOURNAL OF CLINICAL ONCOLOGY Date of publication 2018-4
Co-researcher
Education / Career
Article A phase iii study comparing sb3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in her2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results.
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2018-4
Co-researcher
Education / Career
Article Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Announcements ANNALS OF ONCOLOGY Date of publication 2018-3
Co-researcher
Education / Career
Article Integrated (18)f-fdg pet/mri in breast cancer: early prediction of response to neoadjuvant chemotherapy.
Announcements EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING Date of publication 2018-3
Co-researcher
Education / Career
Article Phase iii, randomized study of dual human epidermal growth factor receptor 2 (her2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with her2-positive, hormone receptor-positive metastatic breast cancer: alternative.
Announcements JOURNAL OF CLINICAL ONCOLOGY Date of publication 2018-3
Co-researcher
Education / Career
Article A phase ii trial of s-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Announcements BMC CANCER Date of publication 2018-3
Co-researcher
Education / Career
Article Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
Announcements GASTRIC CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27147244/
Education / Career
Article Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Announcements ONCOLOGIST Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28652278/
Education / Career
Article Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27737538/
Education / Career
Article Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27456941/
Education / Career
Article Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27488876/
Education / Career
Article Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
Announcements INTERNATIONAL JOURNAL OF CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27501113/
Education / Career
Article Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles
Announcements CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27997703/
Education / Career
Article Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Announcements EUROPEAN JOURNAL OF CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27817944/
Education / Career
Article Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer
Announcements OSTEOPOROSIS INTERNATIONAL Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28083668/
Education / Career
Article Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer
Announcements AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/25171299/
Education / Career
Article Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/27554482/
Education / Career
Article Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer
Announcements GASTRIC CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/26681196/
Education / Career
Article CA19-9 or CEA decline after the first cycle of treatment predicts survival in advanced biliary tract cancer patients treated with S-1 and cisplatin chemotherapy
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28111425/
Education / Career
Article First-in-human Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Announcements ANNALS OF ONCOLOGY Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28119295/
Education / Career
Article Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer
Announcements SUPPORTIVE CARE IN CANCER Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28204996/
Education / Career
Article AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Announcements MOLECULAR CANCER THERAPEUTICS Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28138034/
Education / Career
Article Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
Announcements CANCER RESEARCH AND TREATMENT Date of publication 2017-1
Co-researcher
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/28253566/

전체 메뉴

Find a Doctor

Patients

Education &
Research

Information

About SNUH

전체 검색

전체 검색